Jiangsu GenScript Probio Biotech Joint-stock Co., Ltd. was established on March 29, 2012. It mainly applies synthetic biology and genetic engineering technologies to research, develop and produce virus-like particle (VLP) vaccines and diagnostic reagent enzyme products. Its registered address is in Taicang Biomedical Industrial Park, Suzhou, Jiangsu, with a registered capital of 41.2 million yuan. The founder of GenScript Probio, An Haiqian, and the core members have all received professional training at renowned universities in China and the United States and have many years of work experience at home and abroad. They have successful experience in operating multiple projects. Pragmatism, efficiency, integrity and innovation constitute the corporate culture of GenScript Probio. The company has built a genetic engineering enzyme preparation production platform, with a fermentation culture scale of 28,000 liters per batch and a production line capable of producing up to tens of kilograms of highly purified recombinant protein per batch. The annual capacity of recombinant protein freeze-dried powder exceeds 1,000 kilograms. At present, its main products, including recombinant proteinase K, broad-spectrum endonuclease, RNase and glucose oxidase, all have molecular invention patents. During the COVID-19 pandemic, GenScript Probio supplied hundreds of millions of test-person portions of proteinase K raw materials to nucleic acid diagnostic kit manufacturers at home and abroad, and in the later stage of the pandemic, 90% of its products were exported to the United States. GenScript Probio has passed certifications and qualifications including National High-tech Enterprise, Technology-based Private Enterprise, Jiangsu Province Enterprise Founded by High-level Overseas Talents, and Graduate and Undergraduate Internship Workstation. On the basis of the successful industrialization of recombinant protein diagnostic reagents, and relying on the synthetic biology and genetic engineering technology platforms of its Beijing company, GenScript Probio began in 2009 and first completed the research and development of an H1N1 influenza VLP vaccine. It subsequently developed a series of recombinant virus-like particle (VLP) vaccine products, among which the bivalent foot-and-mouth disease VLP vaccine has completed pilot testing and animal efficacy trials and has filed international PCT patents entering neighboring countries. This recruitment of GenScript Probio mainly aims to strengthen the research and development and production of genetically recombinant VLP vaccines, the research and development of novel mRNA vaccines, and the research and development of novel diagnostic reagents. The company plans to develop several recombinant VLP and mRNA vaccine products within 3-5 years. Therefore, the company's wholly-owned subsidiaries and branches in Shanghai and Beijing are recruiting vaccine and recombinant protein research and development talents with high salaries in Zhangjiang, Shanghai and Yizhuang, Beijing, to grow together with the company and become business partners of GenScript Probio. At present, GenScript Probio is actively advancing the industrialization of VLP vaccines, using its own funds, the capital market and local government support to jointly build a high-tech company oriented toward the development of VLP vaccines and mRNA vaccines, and gradually becoming an enterprise in China's novel genetically recombinant vaccine research, development and production. The company expects to be listed on major capital markets within 2-3 years.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows